Epsilogen announces CTA approval for Phase Ib trial of MOv18 IgE in platinum-resistant ovarian cancer
Epsilogen, a global leader in the development of immunoglobulin E (IgE) antibodies to treat cancer, today announces that the Clinical Trial Application for the Phase Ib trial of MOv18 IgE has been approved by the UK Medicines and Healthcare products Regulatory Agency (MHRA).
The Phase Ib study is expected to initiate later in 2024 and will evaluate the efficacy of MOv18 IgE in patients with platinum-resistant ovarian cancer (PROC).
Dr Tim Wilson, Chief Executive Officer of Epsilogen, said: “This CTA is another significant milestone for Epsilogen and the clinical development of MOv18 IgE. We look forward to progressing MOv18 IgE into a Phase Ib efficacy study later this year as we continue to demonstrate the potential of IgE antibodies as a new, differentiated class of cancer treatments.”
About MOv18 IgE
MOv18 IgE is an immunoglobulin E (IgE) antibody targeting the folate receptor alpha (FR alpha) antigen. FR alpha is present on a variety of cancers including ovarian, endometrial, lung and triple negative breast cancer. Epsilogen has successfully completed a Phase I safety study of MOv18 IgE in PROC patients. The results of the study, published in Nature Communications, found MOv18 IgE to be safe and well tolerated, with evidence of anti-tumour activity observed. Epsilogen, alongside its partner Lonza, also announced the successful completion of large-scale Good Manufacturing Practice (GMP) manufacturing of MOv18 IgE earlier this year.
About the Phase Ib study
The Phase Ib study is designed to confirm the safety and tolerability of MOv18 IgE and demonstrate efficacy in PROC. Following the dose escalation, an expansion cohort will be recruited to make a preliminary assessment of the anti-tumour activity of MOv18 IgE at a selected dose. In addition, delay to disease progression will be assessed along with a number of translational elements to generate further understanding of MOv18 IgE in the study population.
About Epsilogen Ltd
Epsilogen is a global leader in the development of immunoglobulin E (IgE) antibodies to treat cancer. IgE’s natural function is to provide immunological defence against certain parasites. This functionality makes it an ideal treatment of solid tumours due to its strong potency, enhanced tumour access and long tissue half-life.
Epsilogen’s lead product candidate, MOv18 IgE, is the first therapeutic IgE antibody to enter the clinic and encouraging data from a completed Phase I trial demonstrated MOv18 IgE to be safe and well tolerated with early signs of clinical activity. Epsilogen has recently successfully completed large scale GMP manufacture of MOv18 IgE (the first time this has been achieved for an IgE antibody) and will initiate a Phase Ib trial in platinum-resistant ovarian cancer patients later this year. The company is also developing a pipeline of IgE therapies in oncology as well as proprietary platforms including IgE bispecifics and unique IgE/IgG combination antibody molecules (IgEGs) with enhanced functionality.
Epsilogen began operations in 2017 as a spin-out of King’s College London and has attracted venture capital financing from Epidarex Capital, Novartis Venture Fund, 3B Future Health, British Patient Capital, ALSA Ventures and Schroders Capital amongst others. Find out more at epsilogen.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240707808760/en/
Contacts
Communications advisor to Epsilogen Ltd:
Simon Conway
Senior Managing Director
FTI Consulting
epsilogen@fticonsulting.com
+44 (0)20 3727 1000
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Twilio ’s Latest Report Highlights Conversational AI’s Rapid Adoption, Challenges, and Perception Gaps13.11.2025 16:00:00 EET | Press release
Twilio (NYSE: TWLO), the customer engagement platform that drives real-time, personalized experiences for today’s leading brands, today released its Inside the Conversational AI Revolution report.1 Based on a global survey of 457 business leaders and 4,800 consumers across 15 countries, the report unearths major trends related to conversational AI’s adoption, perceptions, and expectations, including a finding that 99% of organizations anticipate their conversational AI strategy will change in the next 12 months. “Businesses that want to successfully deploy conversational AI for customer service, sales, and marketing need to prioritize customer preferences in order to build long-term trust,” said Inbal Shani, chief product officer and head of R&D at Twilio. “As with any new technology, business leaders must be ready to navigate a rapidly changing technical landscape. The key capabilities to prioritize are flexibility, experimentation, and continuous monitoring of the customer experience
Safe Software Ahead of Target to Reach $250M in Revenue by 202813.11.2025 16:00:00 EET | Press release
Safe Software (Safe), the creator of FME, the only All-Data, Any-AI enterprise integration platform with true support for spatial data, today announced strong business momentum and continued progress toward its goal of reaching $250M in revenue by 2028. Building on another year of record performance, Safe Software is ahead of its target, surpassing $100M in annual revenue in FY25, representing nearly 20% year-over-year growth. “Crossing $100M is more than a financial milestone, it’s testament to the significant value FME delivers for our customers every day,” said Don Murray, CEO of Safe Software. “As we advance toward $250M, we remain committed to empowering organizations to unlock the full potential of their data through open, scalable, and intelligent solutions” The company’s employee base increased by 21.8% over the fiscal year, reflecting strategic investments in its people, culture, and innovation to meet global demand. Internally, the growing Safe Software team has embraced AI,
Doha Debates Asks: Is ‘Earned Success’ an Illusion?13.11.2025 15:55:00 EET | Press release
Can success ever be truly earned? In its latest flagship episode, Qatar Foundation’s Doha Debates brings together global thinkers and students for a thought-provoking conversation on whether hard work and talent still determine who rises, or whether “earned success” conceals deeper inequities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251113305464/en/ Doha Debates brings together global thinkers and students for a thought-provoking conversation on whether hard work and talent still determine who rises, or whether “earned success” conceals deeper inequities. (Photo: AETOSWire) Daniel Markovits, Guido Calabresi Professor of Law at Yale Law School, argues that the system meant to promote fairness has instead entrenched inequality. “Meritocracy has become the principal obstacle to equality of opportunity, at least in the rich countries of the world,” he says, warning that competition built on elite education and inherited a
FlightSafety International Announces Release of Industry-Wide Airplane Standard Operating Procedures to Elevate Safety in Business Aviation13.11.2025 15:45:00 EET | Press release
FlightSafety International Inc. today announced the publication of the Airplane Standard Operating Procedures Manual, a landmark resource that establishes consistent, proven practices for business aviation operations worldwide. Developed in collaboration with the National Business Aviation Association (NBAA), aircraft manufacturers, operators, and other leading training experts, the SOPs represent years of industry partnership dedicated to advancing aviation safety. The new manual provides uniform guidance for both single- and multi-pilot operations, reflecting best practices drawn from organizations of all sizes. By promoting widespread adoption of standardized procedures, the SOPs will strengthen consistency across fleets, enhance safety in dynamic crew environments, and generate valuable data to inform future training improvements. “FlightSafety International is proud to lead this initiative and deliver a standard that reflects the input of the entire business aviation community,” s
Experian Named One of the World’s Best Workplaces™ for Second Consecutive Year13.11.2025 15:12:00 EET | Press release
Experian has once again been recognised by Fortune and Great Place to Work® as one of the World’s Best Workplaces™ 2025, marking its second consecutive year on this prestigious global list. This honor places Experian among the top 25 companies worldwide celebrated for exceptional workplace culture, inclusivity, and employee experience. These 25 global leaders were selected from organizations that participated in Great Place to Work’s employee survey process, with over 9 million responses representing more than 25 million employees worldwide. To be considered for the list, companies must have 5,000 or more global employees, be identified as outstanding global employers with recognition on at least five Best Workplaces™ Lists in Asia, Europe, Latin America, Africa, North America, or Australia in 2024 or early 2025. “This award recognizes our people-first culture and our commitment to creating an environment where everyone can thrive,” said Brian Cassin, Experian Chief Executive Officer.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom